Core Points - The company has approved the first unlock period for the reserved grant of restricted stock, allowing 11 eligible incentive recipients to unlock 500,000 shares [2][14][21] - The total share capital of the company is 771,634,398 shares, and the unlocked shares represent 0.0648% of the total share capital [2][21] - The unlock date for the restricted stock is set for December 28, 2023, with a commitment to a 12-month lock-up period, making the shares tradable on July 25, 2025 [19][21] Summary by Sections Incentive Plan Approval - The incentive plan was approved through various board meetings, with the first grant involving 123 recipients and a total of 21,620,000 shares [3][6] - The initial grant price was set at 2.59 CNY per share, later adjusted to 2.49 CNY per share [4][6] Reserved Grant Details - The reserved grant consists of 5,049,910 shares, with similar unlocking conditions as the initial grant [4] - The first unlock period for the reserved shares is set to follow the same schedule as the initial grant [4] Unlock Conditions - The board confirmed that the conditions for unlocking the first reserved grant have been met, allowing for the release of 500,000 shares to the eligible recipients [14][18] - The company will repurchase any shares that do not meet the unlock conditions due to employee departures or other disqualifying factors [18] Stock Structure Changes - Following the unlock, the total number of shares will be adjusted accordingly, with the company maintaining compliance with relevant regulations [22][24] - The board and supervisory committee have both approved the unlock conditions and the related stock repurchase actions [22][23]

证券代码：002688 证券简称：金河生物 公告编号：2025-066 金河生物科技股份有限公司 关于 2023 年限制性股票激励计划预留授予第一个 解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 重要内容提示： （一）本次预留授予第一个解除限售期符合解除限售资格的激励对象 11 名， 可解除限售的限制性股票 500,000 股。 （二）金河生物科技股份有 限公司（以下简称"公司"）目前股本为 （三）本次解除限售的限制性股票限售起始日期为 2023 年 12 月 28 日，承 诺的限售期限为 12 个月，上市流通日为 2025 年 7 月 25 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议案》。鉴于 限售期的解除限售条件已成就，根据公司 2022 年度股东大会对董事会的授权， 公司按规定为预留授予第一个解除限售期符合解除限售资 ...

Group 1 - The company expects a net profit attributable to shareholders for the first half of 2025 to be between 127.43 million and 141.08 million yuan, representing a growth of 40% to 55% compared to 91.02 million yuan in the same period last year [2] - The growth in performance is attributed to the strong sales of veterinary chemical products, particularly the sales of the main product, chlortetracycline, in both domestic and overseas markets, with significant growth in overseas sales [2] - The company's production capacity has increased following the launch of its sixth-phase project, which has ensured supply to both domestic and international markets, contributing to higher profits [2] Group 2 - The global beef cattle industry is entering a new cyclical turning point, with average prices for ground beef in the U.S. rising nearly 12% year-on-year in June, and unprocessed beef steak prices increasing by 8%, reaching historical highs [2] - The rising prices of beef and live cattle in the U.S. are expected to boost the demand for veterinary drugs for live cattle, as local ranchers become less sensitive to drug prices due to increased profits from higher beef prices [2] - The company is the largest producer of veterinary chlortetracycline globally, with 60% to 70% of its products sold overseas, primarily in the U.S., which accounts for about two-thirds of its exports [3] Group 3 - As of July 11, 2025, the wholesale price of beef in China was 63.56 yuan per kilogram, an increase of 4.51% year-on-year, while the price of calves rose to 29.81 yuan per kilogram, up 26.37% year-on-year [4] - The decline in cattle inventory and the rising price of calves are expected to support beef prices in the second half of 2025 and into 2026, indicating a continuation of the beef cycle's prosperity [4] - The company is enhancing its leading position in the chlortetracycline market due to increased usage in large-scale farming and the development of a new animal brucellosis vaccine that has won a major procurement project [4]

金河生物科技股份有限公司 关于 2023 年限制性股票激励计划预留授予第一个 解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 重要内容提示： （一）本次预留授予第一个解除限售期符合解除限售资格的激励对象 11 名， 可解除限售的限制性股票 500,000 股。 证券代码：002688 证券简称：金河生物 公告编号：2025-066 （二）金河生物科技股份有限公司（以下简称"公司"）目前股本为 771,634,398 股，本次预留授予第一个解除限售期可解除限售的限制性股票 500,000 股，占公司目前总股本的 0.0648%。 （三）本次解除限售的限制性股票限售起始日期为 2023 年 12 月 28 日，承 诺的限售期限为 12 个月，上市流通日为 2025 年 7 月 25 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议案》 ...

Group 1 - The animal vaccine sector experienced a decline of 0.96%, ranking among the top losers in the concept sector, with companies like BioShares, Zhongmu, and Pulaike leading the declines [1][2] - Among the animal vaccine stocks, five companies saw price increases, with Luoniushan, Weilan Biology, and Dabeinong rising by 1.42%, 1.38%, and 0.73% respectively [1][2] - The animal vaccine sector faced a net outflow of 218 million yuan from main funds, with 12 stocks experiencing outflows, and six stocks seeing outflows exceeding 10 million yuan [2][3] Group 2 - The top net outflow stock was BioShares, with a net outflow of 128 million yuan, followed by Xianfeng Holdings, Jinhai Biological, and Zhongmu, with net outflows of 41.99 million yuan, 26.07 million yuan, and 25.32 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflow included Dabeinong, Luoniushan, and Weilan Biology, attracting net inflows of 34.95 million yuan, 23.76 million yuan, and 13.06 million yuan respectively [2][3] - The detailed outflow data for the animal vaccine sector shows significant declines in stock prices, with BioShares down by 5.56% and a turnover rate of 11.26% [2][3]

证券代码：002688 证券简称：金河生物 公告编号：2025-065 金河生物科技股份有限公司 关于 2023 年限制性股票激励计划首次授予第二个 解除限售期解除限售股份上市流通的提示性公告 （一）本次首次授予第二个解除限售期符合解除限售资格的激励对象 70 名， 可解除限售的限制性股票 4,326,000 股。 （二）金河生物科技股份有 限公司（以下简称"公司"）目前股本为 （三）本次解除限售的限制性股票限售起始日期为 2023 年 7 月 7 日，承诺 的限售期限为 24 个月，上市流通日为 2025 年 7 月 21 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议案》。鉴于 限售期的解除限售条件已成就，根据公司 2022 年度股东大会对董事会的授权， 公司按规定为首次授予第二个解除限售期符合解除限售资格的激励对象 70 名办 理限制性股票解除限售股份上市流通的相关事宜。本次可解除限售的限制性股票 一、本激励计划已履行的相关审 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-065 金河生物科技股份有限公司 关于 2023 年限制性股票激励计划首次授予第二个 解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 重要内容提示： （一）本次首次授予第二个解除限售期符合解除限售资格的激励对象 70 名， 可解除限售的限制性股票 4,326,000 股。 （二）金河生物科技股份有限公司（以下简称"公司"）目前股本为 771,634,398 股，本次首次授予第二个解除限售期可解除限售的限制性股票 4,326,000 股，占公司目前总股本的 0.5606%。 （三）本次解除限售的限制性股票限售起始日期为 2023 年 7 月 7 日，承诺 的限售期限为 24 个月，上市流通日为 2025 年 7 月 21 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议 ...

金河生物科技股份有限公司（以下简称"公司"）于2025年4月18日及2025 年5月6日分别召开了第六届董事会第二十四次会议和2025年第二次临时股东大 会，审议并通过了《关于变更公司注册资本及修订<公司章程>部分条款的议案》。 具 体 内 容 详 见 公 司 于 2025 年 4 月 19 日 、 2025 年 5 月 7 日 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的相关公告。 公司于2025年6月10日及2025年6月26日分别召开了第六届董事会第二十六 次会议和2025年第三次临时股东大会，审议并通过了《关于增加公司经营范围并 修改<公司章程>的议案》。具体内容详见公司于2025年6月11日、2025年6月27 日于巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 证券代码：002688 证券简称：金河生物 公告编号：2025-064 金河生物科技股份有限公司 关于完成工商变更登记的公告 公司于近日完成了工商变更登记及备案手续，并取得了呼和浩特市行政审批 和政务服务局颁发的《营业执照》，现将具体信息公告如下： 统一社会信用代码：91 ...

Group 1 - The company expects a positive net profit for the first half of 2025, indicating an upward trend in performance [1][2] - The performance forecast period is from January 1, 2025, to June 30, 2025 [1] - The company has not yet audited the performance forecast by a registered accounting firm [1] Group 2 - The sales of the veterinary chemical drug segment have been strong, with increased sales of the main product, oxytetracycline, in both domestic and overseas markets [2] - The completion of the company's sixth-phase project has led to increased production capacity, meeting market demand and generating more profit [2] - The agricultural product processing segment has benefited from a decline in corn prices, contributing positively to overall performance [2]

Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, highlighting changes in control, major asset acquisitions, and performance forecasts for the first half of 2025. Group 1: Control Changes and Stock Suspension - Yangdian Technology is planning a change in control, leading to a stock suspension starting July 14, 2025, for up to 2 trading days [3] - Yuanli Co. is also planning to acquire control of Fujian Tongsheng New Materials Technology, resulting in a stock suspension starting July 14, 2025, for up to 10 trading days [5] - Kanghua Bio is planning a change in control, with stock suspension starting July 14, 2025, for up to 2 trading days [6] - Fuda Alloy is planning to acquire at least 51% of Guangda Electronics, which constitutes a major asset restructuring but will not change the actual controller [7] Group 2: Performance Forecasts - Limin Co. expects a net profit of 260 million to 280 million yuan for H1 2025, a year-on-year increase of 719.25% to 782.27% due to rising sales and prices [9] - Zijin Mining anticipates a net profit of approximately 23.2 billion yuan for H1 2025, a year-on-year increase of about 54% [10] - Chunqiu Electronics forecasts a net profit of 90 million to 110 million yuan for H1 2025, an increase of 236.05% to 310.72% [11] - Jinqilin expects a net profit of around 106 million yuan for H1 2025, a year-on-year increase of 222.36% [12] - Beihua Co. anticipates a net profit of 98 million to 111 million yuan for H1 2025, a year-on-year increase of 182.72% to 220.23% [14] - Guojin Securities expects a net profit of 1.092 billion to 1.137 billion yuan for H1 2025, a year-on-year increase of 140% to 150% [15] - Jiu Yuan Silver Sea forecasts a net profit of 26.49 million to 32.25 million yuan for H1 2025, a year-on-year increase of 130% to 180% [16] - Lankai Technology expects a net profit of 1.1 billion to 1.2 billion yuan for H1 2025, a year-on-year increase of 85.5% to 102.36% [17] - Changcheng Securities anticipates a net profit of 1.335 billion to 1.407 billion yuan for H1 2025, a year-on-year increase of 85% to 95% [18] - Weilan Lithium Core expects a net profit of 300 million to 360 million yuan for H1 2025, a year-on-year increase of 79.29% to 115.15% [19] - Yinlong Co. forecasts a net profit of 161 million to 181 million yuan for H1 2025, a year-on-year increase of 60% to 80% [21] - Aopumai expects a net profit of approximately 37 million yuan for H1 2025, a year-on-year increase of 53.28% [22] - Bailong Dongfang anticipates a net profit of 350 million to 410 million yuan for H1 2025, a year-on-year increase of 50.21% to 75.97% [23] - Shanghai Electric expects a net profit of 1.754 billion to 2.087 billion yuan for H1 2025, a year-on-year increase of 32.18% to 57.27% [24] - Huazhong Securities expects a net profit of 1.035 billion yuan for H1 2025, a year-on-year increase of 44.94% [25] - Bailong Chuangyuan anticipates a net profit of 171 million yuan for H1 2025, a year-on-year increase of 42.68% [26] - Chengyi Pharmaceutical expects a net profit of 107 million to 119 million yuan for H1 2025, a year-on-year increase of 40% to 55% [27] - Jinhai Biological anticipates a net profit of 127 million to 141 million yuan for H1 2025, a year-on-year increase of 40% to 55% [28] - Kanda New Materials expects a net profit of 50 million to 55 million yuan for H1 2025, turning from loss to profit [29] - China Shenhua expects a net profit of 23.6 billion to 25.6 billion yuan for H1 2025, a year-on-year decrease of 8.6% to 15.7% [30] - ST Songfa anticipates a net profit of 580 million to 700 million yuan for H1 2025, turning from loss to profit [31] - Chengxing Co. expects a net profit of 16 million to 23 million yuan for H1 2025, turning from loss to profit [33] - Ningbo Fubon anticipates a net profit of 8 million to 12 million yuan for H1 2025, turning from loss to profit [34] - ST Yundong expects a loss of 100 million to 150 million yuan for H1 2025, worsening from the previous year [35] - Kairuide expects a loss of 15 million to 22 million yuan for H1 2025, turning from profit to loss [36] Group 3: Shareholding Changes - Defu Technology's shareholders plan to reduce their holdings by up to 4.04% [38] - Jinzhen Co.'s shareholders plan to reduce their holdings by up to 3.04% [39] - Shikong Technology's shareholder plans to reduce their holdings by up to 3% [40] - Qilu Bank's shareholder plans to reduce their holdings by up to 1.1% [41] - Zhongci Electronics' shareholder plans to reduce their holdings by up to 1% [42] - Jiamei Packaging's shareholders plan to reduce their holdings by up to 1% [43] - Saike Xide's shareholder plans to reduce their holdings by up to 1% [44] - Gongda High-tech's general manager plans to reduce their holdings by up to 0.3424% [46] - Qingyuan Co.'s shareholder plans to reduce their holdings by up to 273,800 shares [47] Group 4: Major Contracts - Dashijiang expects to win a procurement project worth 122 million yuan [49] - Robotech signed significant daily operational contracts worth approximately 14.18 million USD [50]